glp-1 kidney receptor agonists and next-generation metabolic hormone therapies in chronic disease ICYMI: GLP-1 Agonists Show Promise

10.1016/j.eplepsyres.2023.107076 43

When the body's microscopic power plants fail to generate enough energy, every system, from the brain to the cardiovascular network, begins to struggle

Classifications place the compound under research status, meaning regulatory bodies, namely the Food and Drug Administration (FDA), have not approved it for human therapeutic use

Hashemi MM, Rovig J, Holden BS, et al

40 Insulin receptor is expressed in skeletal muscle, adipocytes, kidneys, brain, blood vessels, heart, liver, pancreatic endocrine cells (such as islet alpha and beta-cells), bone and the GIT

However, caution is warranted